These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 39114297)
1. Intravitreal anti-vascular endothelial growth factor therapy in the treatment of vision loss associated with hematologic malignancy. Toohey TP; Shortt J; John N; Al-Qureshi S; Wickremasinghe SS Am J Ophthalmol Case Rep; 2024 Dec; 36():102095. PubMed ID: 39114297 [TBL] [Abstract][Full Text] [Related]
8. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Virgili G; Curran K; Lucenteforte E; Peto T; Parravano M Cochrane Database Syst Rev; 2023 Jun; 2023(6):CD007419. PubMed ID: 38275741 [TBL] [Abstract][Full Text] [Related]
9. Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report. Yoshimoto M; Takeda N; Yoshimoto T; Matsumoto S J Med Case Rep; 2021 Jul; 15(1):403. PubMed ID: 34311786 [TBL] [Abstract][Full Text] [Related]
10. [What can anti-VEGF therapy achieve in clinical routine? : Effectiveness of anti-VEGF therapy in patients with macular diseases in clinical routine on 1492 eyes in Austria]. Wiesinger K; Reinelt P; Ennemoser A; Edelmayr M; Schönherr U Ophthalmologe; 2017 Jul; 114(7):639-645. PubMed ID: 27815675 [TBL] [Abstract][Full Text] [Related]